Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia

Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia

Background: The introduction of the inactivated poliovirus vaccine (IPV) represents a crucial step in the polio eradication endgame. This trial examined the safety and immunogenicity of IPV given alongside the measles–rubella and yellow fever vaccines at 9 months and when given as a full or fraction...

Full description

Bibliographic Details
Main Authors: Dr. Ed Clarke, MBChB, Yauba Saidu, MD, Jane U Adetifa, MD, Ikechukwu Adigweme, MBBS, Mariama Badjie Hydara, MBBS, Adedapo O Bashorun, MBBS, Ngozi Moneke-Anyanwoke, MBBS, Ama Umesi, MBBS, Elishia Roberts, BSc, Pa Modou Cham, BSc, Michael E Okoye, MBBS, Kevin E Brown, MBBS, Prof. Matthias Niedrig, PhD, Panchali Roy Chowdhury, MSc, Ralf Clemens, MD, Ananda S Bandyopadhyay, MBBS, Jenny Mueller, MD, David J Jeffries, PhD, Prof. Beate Kampmann, MD
Format: Article
Language:English
Published: Elsevier 2016-08-01
Series:The Lancet Global Health
Online Access:http://www.sciencedirect.com/science/article/pii/S2214109X16300754

Similar Items

Similar Items